Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Bevacizumab with EGFR-TKIs in EGFR-Mutant NSCLC
NCT06557096Phase 1Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Overall Survival at 2 years. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06557096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557096.